索诺玛制药公司根据美国化妆品法注册HOCI面部喷雾剂

2025-10-07 20:49

Sonoma Pharmaceuticals (NASDAQ:SNOA) has registered its Microcyn-based facial spray and manufacturing facility under the FDA’s Modernization of Cosmetics Regulation Act of 2022.
The registration allows Sonoma to commercialize HOCl-based products as cosmetics in the U.S., expanding its regulatory footprint.
Sonoma’s facility was already FDA-registered for medical device manufacturing, supporting a broad portfolio in wound care, dermatology, eye care, podiatry, and animal health.
The MoCRA listing positions Sonoma to enter the fast-growing U.S. skincare market, projected to reach $40B by 2030.
The company highlights its patented hypochlorous acid technology as a clean, effective solution for common skin conditions, aligning with rising demand for science-backed skincare.
SNOA shares down 5.5% premarket on Tuesday.
Source: Press release

More on Sonoma Pharmaceuticals